Skip to main content

Prochymal FDA Approval Status

FDA Approved: No
Brand name: Prochymal
Company: Osiris Therapeutics, Inc.
Treatment for: Graft-versus-host disease

Prochymal is a preparation of mesenchymal stem cells formulated for intravenous infusion. Prochymal is currently being evaluated in Phase III trials for steroid refractory graft-versus-host disease (GvHD), acute GvHD, and Crohn's disease.

Development timeline for Prochymal

Jan 15, 2009Osiris and FDA Reach Agreement on Submission of First Marketing Application for a Stem Cell Product

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.